Glasgow-based Mironid raises €39.9 million in Series B to advance rare kidney disease treatment
Mironid, a Glasgow-based biopharmaceutical company, has closed a €39.9 million ($46 million) Series B financing round to push its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. The round was led by Scottish National Investment Bank, which joined a syndicate of existing backers including Roche Venture Fund, Epidarex Capital, Sofinnova […]…
Glasgow-based biopharmaceutical company Mironid has successfully raised €39.9 million ($46 million) in Series B funding to advance its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The round was led by Scottish National Investment Bank and joined by a syndicate of existing backers including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde.
Mironid's CEO, Neil Wilkie, highlighted the significance of the funding, stating that it validates their approach to treating kidney diseases such as ADPKD, which affects over 12 million people worldwide. The funds will be used to progress the clinical development of their first-in-class LoAc small molecule candidate for ADPKD patients, with the aim of transforming the treatment landscape for patients with rare kidney diseases.
Brief written by urgent.news from EU-Startups's own syndicated text. Machine-written — it may contain errors, so check the original before relying on it.
